Sanofi’s cholesterol-fighting biologic drug won’t be pulled from pharmacy shelves, at least not for a few more months.
The U.S. Court of Appeals for the Federal Circuit on Wednesday stayed a Delaware judge’s order enjoining sales of Praluent until the court can process Sanofi and partner Regeneron Pharmaceuticals Inc.’s appeal. Sanofi and a group of amici curiae physicians had argued that enforcing the order would put lives at risk, disrupt medical research, throw Sanofi employees out of work and force the company to renegotiate contracts with insurers and pharmacy benefit managers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
